Gansu Wuwei Cancer Hospital Expert Joins National Lung Cancer Guideline Writing Group
Gansu Wuwei Cancer Hospital Expert Joins National Lung Cancer Guideline Writing Group
Editor’s Note: The Expert Consensus on the Diagnosis and Treatment of Non‑Small Cell Lung Cancer with MET Alterations (2026 Edition) is China's first authoritative, systematic industry standard specifically addressing MET‑altered lung cancer. It holds guiding significance for the precision diagnosis and treatment of lung cancer nationwide.
Recently, it was announced that Dr. Li Zhengguo, Director of the Department of Respiratory and Critical Care Medicine at Gansu Wuwei Cancer Hospital, has been selected as a member of the expert writing group for the guidelines. He participated fully in the writing, revision, and review process, making our hospital the first in Wuwei City and one of the few in the region to contribute to the development of national‑level lung cancer guidelines. This represents a breakthrough achievement for our respiratory medicine department at the level of national academic standard‑setting.
1. Contributing to National Gold‑Standard Guidelines, Establishing a Regional Academic Hub for Lung Cancer Care
MET gene alterations are among the most critical and cutting‑edge precision therapeutic targets in non‑small cell lung cancer, encompassing complex subtypes including MET exon 14 skipping mutations, MET amplification, and protein overexpression. These alterations present diagnostic and therapeutic challenges due to their complexity and rapidly evolving landscape, making them a key focus in precision and individualized lung cancer care. The Expert Consensus on the Diagnosis and Treatment of Non‑Small Cell Lung Cancer with MET Alterations (2026 Edition) is China's first systematic, standardized authoritative guideline for MET‑altered lung cancer. It holds mandatory, guiding, and standardizing value for lung cancer screening, precision testing, targeted therapy, and whole‑course management at hospitals across the country, serving as the "gold standard" for clinical lung cancer care in China.
Being selected for the national guideline writing team represents authoritative national recognition of the clinical strength, disciplinary development, and regional leadership of our Department of Respiratory and Critical Care Medicine. It is also a landmark achievement reflecting the hospital's sustained commitment to integrating research with clinical practice, advancing precision cancer care, and continuously strengthening its core competitiveness.
2. Technology‑Driven Excellence: A Minimally Invasive and Precision System Establishes a Regional Benchmark
Our Department of Respiratory and Critical Care Medicine is a provincial‑level key discipline in Gansu Province and serves as a core benchmark for precision lung cancer care, management of complex respiratory critical illnesses, and minimally invasive interventional pulmonology in Wuwei and the surrounding regions. Over the years, the department has focused on early lung cancer screening and diagnosis, precision targeted therapy, local minimally invasive treatment, and standardized whole‑course management of advanced lung cancer. It has consistently tackled complex and drug‑resistant lung cancer cases, achieving comprehensive diagnostic and treatment capabilities that are among the strongest in the region.
Lung Cancer Brachytherapy (Radioactive Seed Implantation)
The department has established a comprehensive and precise diagnostic system, enabling blind‑spot‑free, full‑coverage precision biopsy of pulmonary lesions. It was the first in the Wuwei region to independently perform high‑difficulty CT‑guided percutaneous lung biopsy, and among the earliest in the province to introduce endobronchial ultrasound (EBUS) and EBUS‑guided fine‑needle aspiration. Combined with medical thoracoscopy, EBUS, and full‑spectrum next‑generation sequencing (NGS) genetic testing, the department has built a mature, safe, and precise pathological diagnostic system for lung tumors. This system provides accurate pathological evidence for precision lung cancer subtyping, targeted therapy, and immunotherapy, significantly improving the early diagnosis rate of lung cancer in the region.
Medical Thoracoscopy
The department offers a comprehensive range of minimally invasive interventional procedures. It routinely and independently performs advanced techniques including microwave ablation for lung cancer, tumor radioactive seed implantation, bronchopleural fistula closure, airway balloon dilation, and complex bronchial stent placement. With a full spectrum of well‑established procedures, the department leverages the advantages of minimally invasive, precise, safe, and fast‑recovery approaches to provide individualized comprehensive treatment options for patients who are inoperable, elderly, have multiple comorbidities, or are living with advanced lung cancer. These interventions effectively prolong survival and improve quality of life for a large number of patients with respiratory and oncologic conditions across the Hexi region.
Endobronchial Ultrasound
3. Research‑Driven Excellence: Delivering High‑Quality Clinical Outcomes
The department is committed to the mutually reinforcing advancement of clinical practice and research. Leveraging multiple national and provincial platforms — including our hospital's Heavy Ion Cancer Treatment Center, National Endoscopy Training Base, and National Early Diagnosis and Treatment Demonstration Base — the department has been deeply engaged in both basic and clinical research on lung cancer. In recent years, the department has led or participated in 6 provincial and municipal research projects, received municipal science and technology progress awards, and published over 20 papers in national core journals, consistently delivering high‑quality clinical research outcomes. Beyond advancing in‑hospital technical capabilities and managing complex cases, the team actively contributes to national standard‑setting and the dissemination of cutting‑edge diagnostic and treatment concepts, driving the standardization of respiratory disease care in the region through academic leadership.
4. A New Starting Point: Empowering Regional Precision Cancer Care Across the Continuum
Being selected to contribute to this national lung cancer consensus is a clear affirmation that the clinical reasoning, technical standards, and treatment philosophy of our Department of Respiratory and Critical Care Medicine are fully aligned with national guideline standards. It reflects the comprehensive strength of our hospital's disciplines and its regional academic influence. This achievement is not merely a professional honor — it validates the department's commitment to evidence‑based practice, its capacity to participate in national‑level academic work, and its role as a regional leader in lung cancer care. It also reinforces the hospital's broader mission of integrating clinical excellence with academic contribution, ensuring that patients in the region benefit from care that meets the highest national standards.
Looking ahead, our hospital will take this achievement as an opportunity to fully translate the outcomes of the national guidelines into clinical practice. Leveraging the heavy ion platform, we will build an integrated multidisciplinary standardized whole‑course management system for lung cancer. Grounded in the epidemiological characteristics of Northwest China, we will deepen clinical research, refine regional early screening networks, and reduce the proportion of advanced‑stage lung cancer from the outset. At the same time, we will disseminate standardized clinical experience to primary‑care institutions, driving an overall improvement in regional diagnostic and treatment capabilities and effectively strengthening the respiratory health defense line in the Hexi Corridor.
Writer: Department of Respiratory and Critical Care Medicine
First Review: Yang Yang
Second Review: Guo Yishan
Third Review: Cai Qinghua
Gansu Wuwei Cancer Hospital (Wuwei Institute of Medical Sciences)
（甘）医广【2025】第11-14-387号
